Comparative Pharmacology
Head-to-head clinical analysis: GABLOFEN versus ROBAXIN 750.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABLOFEN versus ROBAXIN 750.
GABLOFEN vs ROBAXIN-750
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
750 mg orally four times daily (total daily dose 3000 mg).
None Documented
None Documented
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant